Getinge (SE:GETI.B)
:GETI.B
Top Page
Getinge
(GETI.B)
Select Model
Select Model
Rating:57Neutral
Price Target:
kr203.00
▼(-6.41% Downside)
Action:ReiteratedDate:01/30/26
The score is held back mainly by weak technical momentum (trading below key moving averages with negative MACD). Financials are stable but not strong, reflecting flat growth and uneven profitability/cash flow, while valuation is mixed with a moderate dividend partially offsetting a mid-to-high P/E.
Positive Factors
Recurring revenue & service contracts
Getinge's mix of direct product sales plus ongoing maintenance, service contracts and consumables builds recurring revenue. That recurring income increases customer stickiness, stabilizes cash flows and supports durable margin and investment planning over the next 2–6 months.
Negative Factors
Flat and uneven revenue trend
Stagnant top‑line growth limits scale benefits and reduces potential for operating‑leverage gains. Over the medium term, flat revenues constrain reinvestment capacity, weaken competitive positioning versus faster‑growing peers and raise execution risk for long‑term targets.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue & service contracts
Getinge's mix of direct product sales plus ongoing maintenance, service contracts and consumables builds recurring revenue. That recurring income increases customer stickiness, stabilizes cash flows and supports durable margin and investment planning over the next 2–6 months.
Read all positive factors
Getinge (GETI.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr50.25B
Dividend Yield2.16%
Average Volume (3M)472.77K
Price to Earnings (P/E)26.4
Beta (1Y)0.78
Revenue Growth6.74%
EPS Growth21.40%
CountrySE
Employees11,827
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)4.45
Shares Outstanding254,152,370
10 Day Avg. Volume671,507
30 Day Avg. Volume472,771
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)2.03
Price to Sales (P/S)1.70
P/FCF Ratio22.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr235.00Price Target Upside8.34% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)11.57
Revenue Forecast (FY)kr34.87B
Getinge Business Overview & Revenue Model
Company Description
Getinge (GETI.B) is a global medical technology company that specializes in providing innovative solutions for healthcare and life sciences. The company operates primarily in three sectors: Surgical Workflows, Critical Care, and Life Science. Geti...
How the Company Makes Money
Getinge generates revenue through the sale of medical devices, equipment, and services across its key sectors. The company has established multiple revenue streams, including the direct sale of its products to healthcare facilities, ongoing mainte...
Getinge Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
72
Positive
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 34.97B | 34.76B | 31.83B | 28.29B | 27.05B |
| Gross Profit | 15.54B | 16.15B | 14.49B | 13.41B | 13.58B |
| EBITDA | 5.85B | 5.31B | 5.93B | 5.73B | 6.15B |
| Net Income | 2.26B | 1.64B | 2.41B | 2.49B | 2.97B |
Balance Sheet | |||||
| Total Assets | 56.51B | 63.92B | 53.59B | 52.03B | 44.55B |
| Cash, Cash Equivalents and Short-Term Investments | 3.40B | 2.96B | 2.73B | 5.68B | 4.08B |
| Total Debt | 10.88B | 10.73B | 8.08B | 5.82B | 4.31B |
| Total Liabilities | 27.01B | 30.71B | 23.18B | 21.58B | 19.38B |
| Stockholders Equity | 29.43B | 33.01B | 30.17B | 30.04B | 24.75B |
Cash Flow | |||||
| Free Cash Flow | 2.63B | 3.27B | 1.60B | 2.23B | 5.63B |
| Operating Cash Flow | 3.95B | 4.58B | 2.96B | 3.37B | 6.56B |
| Investing Cash Flow | -2.96B | -4.55B | -6.54B | -1.47B | -1.33B |
| Financing Cash Flow | -765.00M | 504.00M | 511.00M | -500.00M | -7.24B |
Getinge Technical Analysis
Negative
216.90
Price Trends
197.48
Negative
206.43
Negative
204.37
Negative
Market Momentum
-4.41
Negative
38.04
Neutral
64.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GETI.B, the sentiment is Negative. The current price of 216.9 is above the 20-day moving average (MA) of 189.76, above the 50-day MA of 197.48, and above the 200-day MA of 204.37, indicating a bearish trend. The MACD of -4.41 indicates Negative momentum. The RSI at 38.04 is Neutral, neither overbought nor oversold. The STOCH value of 64.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GETI.B.
Getinge Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | kr3.52B | 24.49 | 17.89% | 1.61% | 1.53% | 0.79% | |
67 Neutral | kr42.65B | 68.38 | 27.98% | 0.43% | 10.08% | 68.12% | |
59 Neutral | kr7.02B | 233.59 | 1.20% | ― | 8.39% | -85.36% | |
57 Neutral | kr50.25B | 26.39 | 6.91% | 2.16% | 6.74% | 21.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr12.46B | -3.70 | 3.34% | 0.80% | -1.29% | ― | |
44 Neutral | kr876.15M | -17.24 | -4.42% | ― | 13.48% | 28.98% |
* Healthcare Sector Average
SE:GETI.B
Getinge
184.50
-25.89
-12.31%
SE:VITR
Vitrolife AB
92.00
-68.02
-42.51%
SE:CEVI
CellaVision AB
147.40
-17.50
-10.61%
SE:XVIVO
Xvivo Perfusion AB
222.80
-58.70
-20.85%
SE:SECT.B
Sectra AB Class B
218.60
-19.21
-8.08%
SE:SEDANA
Sedana Medical AB
8.82
0.89
11.22%
Getinge Corporate Events
Getinge Ends 2025 With Record Q4, Strong Organic Growth and Higher Underlying Profitability
Jan 27, 2026
Getinge reported a record fourth quarter and full-year 2025 organic sales growth of 4.9%, at the upper end of its guidance, driven by higher demand for ECLS consumables, acute care therapies, transplant care and ventilators, while Surgical Workflo...
Getinge Schedules Conference Call for 2025 Year-End Report
Jan 13, 2026
Getinge will publish its Year-End Report for 2025 on January 27, 2026, and will host a same-day conference call led by President CEO Mattias Perjos and CFO Agneta Palmér for fund managers, analysts and media. The call, which will be accompan...
Getinge to Strengthen Board with Former Novo Nordisk Executive Camilla Sylvest
Dec 18, 2025
Getinge’s Nomination Committee plans to propose seasoned healthcare executive Camilla Sylvest for election to the company’s Board of Directors at the 2026 Annual General Meeting, while long-serving board member Malin Persson has declin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.